Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs BIO-TECHNE Corp (TECH) Price & Performance

Apartment Investment and Management CoTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs BIO-TECHNE Corp — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $380.52M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 29.5× Apartment Investment and Management Co's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.

AIVTECH
Market Cap
$380.52M$11.24B
Sector
Real EstateHealth
52-Week High
$7.93$72.29
52-Week Low
$2.61$43.31
Enterprise Value
$742.67M$11.32B
Dividend Yield
0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.66, up 0.38% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 400.05% in 2025, driven by a significant tax benefit, though revenue declined to $138.49 million. Earnings history shows mixed quarterly results, with two beats and two misses against expectations. Analyst consensus is mixed with a hold rating from two of three analysts.

The outlook is cautious due to volatile earnings and declining revenue, offset by strong profitability metrics and a dividend announcement. Key risks include inconsistent financial performance and high debt levels. Upside potential exists if the company stabilizes revenue growth and maintains improved margins.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH